Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell of proximal tubule | 4 studies | 29% ± 5% | |
hepatocyte | 4 studies | 56% ± 25% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 25% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 16072.65 | 226 / 226 | 95% | 236.95 | 386 / 406 |
kidney | 100% | 952.66 | 89 / 89 | 43% | 7.26 | 383 / 901 |
prostate | 91% | 13.67 | 224 / 245 | 23% | 2.54 | 117 / 502 |
pancreas | 97% | 21.70 | 318 / 328 | 7% | 0.25 | 13 / 178 |
stomach | 94% | 191.49 | 338 / 359 | 6% | 0.38 | 16 / 286 |
bladder | 95% | 12.52 | 20 / 21 | 3% | 0.25 | 15 / 504 |
ovary | 97% | 28.32 | 175 / 180 | 0% | 0.04 | 2 / 430 |
uterus | 95% | 19.61 | 162 / 170 | 2% | 0.05 | 8 / 459 |
blood vessel | 93% | 18.04 | 1238 / 1335 | 0% | 0 | 0 / 0 |
thymus | 91% | 13.81 | 597 / 653 | 0% | 0.00 | 1 / 605 |
intestine | 77% | 8.38 | 745 / 966 | 4% | 0.51 | 20 / 527 |
breast | 77% | 13.09 | 354 / 459 | 2% | 0.14 | 23 / 1118 |
skin | 75% | 10.37 | 1359 / 1809 | 0% | 0.02 | 2 / 472 |
esophagus | 69% | 7.49 | 1000 / 1445 | 6% | 0.73 | 11 / 183 |
lung | 71% | 12.23 | 412 / 578 | 4% | 0.28 | 44 / 1155 |
adipose | 73% | 11.01 | 874 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 71% | 7.38 | 182 / 258 | 0% | 0 | 0 / 230 |
spleen | 63% | 23.80 | 151 / 241 | 0% | 0 | 0 / 0 |
heart | 50% | 5.77 | 429 / 861 | 0% | 0 | 0 / 0 |
brain | 48% | 3.87 | 1277 / 2642 | 0% | 0.02 | 2 / 705 |
peripheral blood | 42% | 39.46 | 388 / 929 | 0% | 0 | 0 / 0 |
muscle | 16% | 0.97 | 130 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0070328 | Biological process | triglyceride homeostasis |
GO_0048844 | Biological process | artery morphogenesis |
GO_0001525 | Biological process | angiogenesis |
GO_0055091 | Biological process | phospholipid homeostasis |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0007160 | Biological process | cell-matrix adhesion |
GO_0007165 | Biological process | signal transduction |
GO_0008203 | Biological process | cholesterol metabolic process |
GO_0006631 | Biological process | fatty acid metabolic process |
GO_0055090 | Biological process | acylglycerol homeostasis |
GO_0050996 | Biological process | positive regulation of lipid catabolic process |
GO_0010519 | Biological process | negative regulation of phospholipase activity |
GO_0009725 | Biological process | response to hormone |
GO_0007229 | Biological process | integrin-mediated signaling pathway |
GO_0019915 | Biological process | lipid storage |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0006071 | Biological process | glycerol metabolic process |
GO_0006644 | Biological process | phospholipid metabolic process |
GO_0055088 | Biological process | lipid homeostasis |
GO_0051005 | Biological process | negative regulation of lipoprotein lipase activity |
GO_0042632 | Biological process | cholesterol homeostasis |
GO_0009395 | Biological process | phospholipid catabolic process |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005769 | Cellular component | early endosome |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0009986 | Cellular component | cell surface |
GO_0030027 | Cellular component | lamellipodium |
GO_0008201 | Molecular function | heparin binding |
GO_0004857 | Molecular function | enzyme inhibitor activity |
GO_0008083 | Molecular function | growth factor activity |
GO_0005178 | Molecular function | integrin binding |
GO_0004859 | Molecular function | phospholipase inhibitor activity |
Gene name | ANGPTL3 |
Protein name | Angiopoietin-related protein 3 (Angiopoietin-5) (ANG-5) (Angiopoietin-like protein 3) [Cleaved into: ANGPTL3(17-221); ANGPTL3(17-224)] |
Synonyms | ANGPT5 UNQ153/PRO179 |
Description | FUNCTION: Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism . Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1 . Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids . Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol . Suppresses LPL specifically in oxidative tissues which is required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT (By similarity). Contributes to lower plasma levels of low density lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway implicating APOE and LDLR. May stimulate hypothalamic LPL activity (By similarity). .; FUNCTION: [ANGPTL3(17-221)]: In vitro inhibits LPL activity; not effective on GPIHBP1-stabilized LPL. .; FUNCTION: Involved in angiogenesis. Binds to endothelial cells via integrin alpha-V/beta-3 (ITGAV:ITGB3), activates FAK, MAPK and Akt signaling pathways and induces cell adhesion and cell migration . Secreted from podocytes, may modulate properties of glomerular endothelial cells involving integrin alpha-V/beta-3 and Akt signaling . May increase the motility of podocytes. May induce actin filament rearrangements in podocytes implicating integrin alpha-V/beta-3 and Rac1 activation. Binds to hematopoietic stem cells (HSC) and is involved in the regulation of HSC activity probably implicating down-regulation of IKZF1/IKAROS (By similarity). . |
Accessions | ENST00000371129.4 Q9Y5C1 |